Sibeprenlimab clinical trials
Also written VIS649.
ClinicalTrials.gov finds 8 studies for sibeprenlimab. How that becomes 8 here
Every study that search finds has been read, to see whether and how it gives sibeprenlimab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 8Found by its intervention search · See all 8 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 8 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 9Give sibeprenlimab to participants
- −1Compare another treatment with it
- 8Test it: the count on this site
Get an email when these change. Save the sibeprenlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Nov 2025 · VOYXACT · BLA 761434 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Otsuka Beijing Research Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Sibeprenlimab is the comparator. A study of two new drugs counts under both.
- 1Povetacicept · Vertex Pharmaceuticals Incorporated · next primary completion Dec 2027
Reaching primary completion within a year · 1
Studies that test sibeprenlimab.
- Mar 2027A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sPhase 2 · Otsuka Pharmaceutical Development & Commercialization, Inc.
Studies
Open first, then newest update. How each study uses sibeprenlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 8
- Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07770815In children and adolescents with IgA nephropathyWritten as SibeprenlimabReport a problem
- A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07861113In membranous nephropathy and other glomerular diseasesWritten as SibeprenlimabReport a problem
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Enrolling by invitationPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248659Open-label extension in IgA nephropathyWritten as Sibeprenlimab 400 mg s.c. Q4weeksReport a problem
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sActive, not recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06928142In Sjögren'sWritten as SibeprenlimabReport a problem
- Phase 2b Open-Label Repeat Kidney Biopsy StudyActive, not recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06740526Repeat kidney biopsies in IgA nephropathyWritten as SibeprenlimabReport a problem
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Active, not recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248646On the US labelIn IgA nephropathy (VISIONARY)Written as Sibeprenlimab 400 mgReport a problem
- First in Human Study to Assess Safety of VIS649 in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03719443First in human, in healthy subjectsWritten as VIS649Report a problem
- Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy SubjectCompletedPhase 1Otsuka Beijing Research InstituteNCT07105124In healthy Chinese subjectsWritten as SibeprenlimabReport a problem
Behind its US label · 1 — the studies the FDA label of VOYXACT describes
From the Clinical Studies section of VOYXACT (2026-03), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 7 — no other medicine in its arm
- A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07861113In membranous nephropathy and other glomerular diseasesWritten as SibeprenlimabReport a problem
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Enrolling by invitationPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248659Open-label extension in IgA nephropathyWritten as Sibeprenlimab 400 mg s.c. Q4weeksReport a problem
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sActive, not recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06928142In Sjögren'sWritten as SibeprenlimabReport a problem
- Phase 2b Open-Label Repeat Kidney Biopsy StudyActive, not recruitingPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT06740526Repeat kidney biopsies in IgA nephropathyWritten as SibeprenlimabReport a problem
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Active, not recruitingPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05248646On the US labelIn IgA nephropathy (VISIONARY)Written as Sibeprenlimab 400 mgReport a problem
- First in Human Study to Assess Safety of VIS649 in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03719443First in human, in healthy subjectsWritten as VIS649Report a problem
- Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy SubjectCompletedPhase 1Otsuka Beijing Research InstituteNCT07105124In healthy Chinese subjectsWritten as SibeprenlimabReport a problem
Tested with established drugs · 1 — they are given beside it
As the comparator · 1 — what is tested is compared with sibeprenlimab
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT07890909Comparator to povetacicept's auto-injector, on participant experienceWritten as SibeprenlimabReport a problem
Codes
What other systems call sibeprenlimab · ClinicalTrials.gg INT002181
- MeSH (NLM) C000731962sibeprenlimabOne source NLM
- UNII (FDA) GHX28QZ7DDSIBEPRENLIMABConfirmed FDA, NLM
- NCI Thesaurus C179120SibeprenlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731962 | sibeprenlimab | One source NLM |
| UNII (FDA) | GHX28QZ7DD | SIBEPRENLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C179120 | Sibeprenlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.